Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 6, Pages 1580-1587
Publisher
Oxford University Press (OUP)
Online
2013-03-06
DOI
10.1093/annonc/mdt028
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Similarities in treatment (Tx) patterns and clinical outcomes (CO) in patients (pts) with metastatic colorectal cancer (mCRC) initially treated with FOLFOX/BV or FOLFIRI/BV: Results from ARIES, a bevacizumab (BV) observational study.
- (2017) J. C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer
- (2012) Jeffrey A. Meyerhardt et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
- (2012) E. Diaz-Rubio et al. ONCOLOGIST
- Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group
- (2011) Nicolas Moosmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
- (2010) Jean-Yves Douillard et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
- (2010) Janja Ocvirk WORLD JOURNAL OF GASTROENTEROLOGY
- Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
- (2009) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- 6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study)
- (2009) M. Ducreux et al. EJC SUPPLEMENTS
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
- (2009) M. Kozloff et al. ONCOLOGIST
- Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials
- (2008) Hendrik-Tobias Arkenau et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer
- (2008) Jim Cassidy et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
- (2008) Leonard B. Saltz et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
- (2008) Daniel G. Haller et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set
- (2008) Michael J. O'Connell et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
- (2008) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now